Topic Hub
39 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 39 of 39 clinical reviews.
A clinical guide to abaloparatide (Tymlos) for osteoporosis, covering mechanism, trial data from ACTIVE and ACTIVExtend, dosing, side effects, cost, and head-to-head comparisons with teriparatide, alendronate, risedronate, ibandronate, and zoledronic acid.
Read clinical reviewA clinician-reviewed guide to alendronate (Fosamax) covering mechanism of action, doses, fracture-reduction data, side effects, and how it stacks up against risedronate, ibandronate, zoledronic acid, and denosumab.
Read clinical reviewA clinical comparison of alendronate (oral weekly) vs zoledronic acid (annual IV infusion) for osteoporosis, covering fracture-reduction data, dosing, side effects, and how both stack up against denosumab, teriparatide, abaloparatide, and romosozumab.
Read clinical reviewBisphosphonates are effective for osteoporosis, but long-term use raises questions about atypical fractures, osteonecrosis of the jaw, and how to stop drugs like Prolia safely. Get evidence-based answers here.
Read clinical reviewA physician-reviewed guide to atypical femoral fractures (AFFs), including their link to bisphosphonates and denosumab, osteonecrosis of the jaw, denosumab rebound on discontinuation, diagnosis, and management.
Read clinical reviewA clinician-reviewed guide to bisphosphonate drug holidays covering stopping criteria, duration by agent, fracture risk monitoring, denosumab scheduling, and vitamin D repletion dosing.
Read clinical reviewCompare bisphosphonates (alendronate, zoledronic acid) and denosumab (Prolia) for osteoporosis. Evidence-based analysis of efficacy, fracture reduction, side effects, cost, and switching protocols.
Read clinical reviewBariatric surgery accelerates bone loss in every patient subgroup. Learn the mechanisms, monitoring schedule, supplement protocols, and when to start antiresorptive therapy, with evidence from named trials and clinical guidelines.
Read clinical reviewA comprehensive clinical guide to osteoporosis covering bone remodeling biology, DXA diagnosis, fracture risk, and treatments from bisphosphonates to HRT and TRT, with citations to primary medical literature.
Read clinical reviewAromatase inhibitors accelerate bone loss by suppressing estrogen. Learn evidence-based strategies to protect bone density during AI therapy, including bisphosphonates, denosumab, and lifestyle modifications.
Read clinical reviewGlucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis. Learn how long-term steroid use damages bone, who needs treatment, and which medications protect against fractures.
Read clinical reviewA physician-reviewed guide to calcitonin (Miacalcin) for osteoporosis: how it works, FDA-approved doses, safety profile, and head-to-head comparison with alendronate, risedronate, ibandronate, and zoledronic acid.
Read clinical reviewA complete clinical guide to denosumab (Prolia) for osteoporosis: mechanism, dosing, fracture-risk data, comparisons with alendronate, risedronate, ibandronate, and zoledronic acid, plus guidance on discontinuation and rebound risk.
Read clinical reviewComplete guide to the denosumab (Prolia) every-6-month injection schedule, including timing windows, lab monitoring, vitamin D repletion, bisphosphonate transition protocols, and rebound fracture prevention.
Read clinical reviewStopping denosumab without a transition plan triggers rapid, severe bone loss and a spike in vertebral fracture risk. Learn the mechanism, the clinical evidence, and the only proven prevention strategy.
Read clinical reviewLearn the difference between T-scores and Z-scores on a DEXA scan, what each number tells you about fracture risk, and when your doctor uses one over the other.
Read clinical reviewEvidence-based review of weighted vest training for bone density. Covers clinical trial results, optimal protocols, and how mechanical loading compares to pharmacotherapy for osteoporosis prevention.
Read clinical reviewA clinical comparison of romosozumab (Evenity) and teriparatide (Forteo) for osteoporosis, covering BMD gains, fracture reduction, dosing, side effects, cost, and sequencing strategies.
Read clinical reviewA detailed clinical comparison of teriparatide (Forteo) and abaloparatide (Tymlos) for osteoporosis, covering fracture data, dosing, side effects, cost, and how each fits into a broader treatment sequence.
Read clinical reviewStopping Prolia (denosumab) without a transition plan can trigger rebound vertebral fractures within months. Learn the evidence-based protocol for safe discontinuation, including bisphosphonate bridging, monitoring timelines, and DEXA follow-up.
Read clinical reviewProlia (denosumab) costs roughly $1,800 per injection without insurance. Learn about Medicare Part B coverage, copay assistance, and how Prolia pricing compares to bisphosphonates and anabolic agents like Evenity and Forteo.
Read clinical reviewA clinician-reviewed guide to ibandronate (Boniva) covering FDA-approved doses, fracture-risk data, head-to-head comparisons with alendronate, risedronate, zoledronic acid, and denosumab, plus monitoring protocols and switching criteria.
Read clinical reviewA clinical guide to insurance coverage for anabolic osteoporosis drugs including teriparatide (Forteo), abaloparatide (Tymlos), and romosozumab (Evenity), with costs, prior auth tips, and appeal strategies.
Read clinical reviewCollagen makes up roughly 30% of bone by weight, but does supplementing it improve bone density? We review the RCTs, compare collagen to standard osteoporosis therapies, and explain who may benefit.
Read clinical reviewMale osteoporosis affects roughly 2 million men in the U.S. and causes 80,000 hip fractures per year. Learn the causes, screening criteria, and FDA-approved treatments backed by clinical trial data.
Read clinical reviewOsteonecrosis of the jaw (ONJ) is a rare but serious complication of bisphosphonates and denosumab. Learn the real incidence, risk factors, prevention steps, and what to do if you develop ONJ while on osteoporosis treatment.
Read clinical reviewA clinician-reviewed guide to osteopenia covering T-score thresholds, fracture risk, calcium and vitamin D targets, bisphosphonate protocols, and how postmenopausal, male, and steroid-induced bone loss differ.
Read clinical reviewA clinician-reviewed guide to osteoporosis covering bone density thresholds, DXA scanning, postmenopausal bone loss, male osteoporosis, steroid-induced disease, and FDA-approved treatments including bisphosphonates, denosumab, and romosozumab.
Read clinical reviewA complete clinical guide to Paget's disease of bone, covering pathophysiology, diagnostic criteria, bisphosphonate therapy, and how it differs from osteoporosis and osteopenia.
Read clinical reviewPostmenopausal bone loss accelerates rapidly after menopause due to estrogen withdrawal. Learn the science, screening timelines, drug options, and lifestyle strategies that protect bone density.
Read clinical reviewA physician-reviewed comparison of denosumab (Prolia) vs bisphosphonates (alendronate, zoledronic acid, risedronate) covering efficacy, fracture risk, dosing, side effects, and how to switch safely.
Read clinical reviewA clinician-reviewed guide to raloxifene (Evista) for postmenopausal osteoporosis and breast cancer risk reduction, including dosing, side effects, and head-to-head comparisons with alendronate, risedronate, ibandronate, and zoledronic acid.
Read clinical reviewComplete clinical guide to risedronate (Actonel): doses, fracture-reduction data, side effects, and head-to-head comparisons with alendronate, ibandronate, zoledronic acid, and denosumab.
Read clinical reviewA clinical deep-dive into romosozumab (Evenity) for osteoporosis, including how it works, trial data, and how it stacks up against alendronate, risedronate, ibandronate, and zoledronic acid.
Read clinical reviewA clinician-reviewed guide covering who actually needs calcium and vitamin D supplements, safe dosing, bisphosphonate safety, how to stop Prolia, DEXA T-score vs Z-score, and whether weighted vests build bone density.
Read clinical reviewGlucocorticoid-induced osteoporosis is the most common secondary cause of bone loss. Learn how steroids damage bone, who is at risk, and what treatments the 2022 ACR guidelines recommend.
Read clinical reviewTeriparatide (Forteo) is an anabolic bone-building agent for severe osteoporosis. Learn how it works, who qualifies, expected BMD gains, side effects, cost, and how it compares to alendronate, risedronate, ibandronate, and zoledronic acid.
Read clinical reviewA clinical guide to vertebral compression fractures covering diagnosis, conservative management, vertebroplasty, kyphoplasty, and osteoporosis prevention strategies backed by trial data.
Read clinical reviewA clinician-reviewed guide to zoledronic acid (Reclast): how the annual IV infusion works, fracture-reduction data from HORIZON-PFT, dosing, side effects, and head-to-head comparisons with alendronate, risedronate, ibandronate, and denosumab.
Read clinical review